Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-FLT3 CAR-T (Soochow University)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-FLT3 CAR-T (Soochow University) is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by The First Affiliated Hospital of Soochow University for the treatment of acute myeloid leukemia (AML). The therapy consists of autologous or allogeneic T-cells genetically engineered to express a CAR that specifically targets Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase frequently overexpressed or mutated in AML. Upon administration, these CAR-T cells recognize and bind to FLT3-positive leukemic cells, leading to T-cell activation, proliferation, and the targeted destruction of the malignant cells. It is currently being evaluated in Phase 1/2 clinical trials for patients with relapsed or refractory FLT3-positive AML.
- Other names
- anti-FLT3 CAR-Tanti-FLT-3 CAR-Tanti-FLT 3 CAR-Tanti-FLT3 chimeric antigen receptor engineered T-cellsanti-FLT-3 chimeric antigen receptor engineered T-cellsanti-FLT 3 chimeric antigen receptor engineered T-cellsanti-FLT3 CAR-T cellsanti-FLT-3 CAR-T cellsanti-FLT 3 CAR-T cells
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on anti-FLT3 CAR-T (Soochow University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-FLT3 CAR-T (Soochow University).